Skip to content
TriangleGet started
← Full study record

NCT04322539 · OUTCOME

Health Care Resource Utilization: Duration of Hospital Visits by Participants

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer · Source last updated 2025-04-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
days per visit
Interval / dispersion
Standard Deviation
Time frame
From start of study drug administration up to 22 months

What was measured

Duration of hospital visit was calculated as = stop date - start date + 1. Mean and standard deviation data for duration of hospital visits (in days) by participants was reported in this outcome measure.

Analysis population: ITT population included all randomized participants.

Groups in this outcome

Fruquintinib + BSC Group

Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).

Placebo + BSC Group

Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Fruquintinib + BSC Group461
Placebo + BSC Group230

Analysis denominator · Number of visits

GroupSource count
Fruquintinib + BSC Group545
Placebo + BSC Group232

Reported measurements

Source class 1
Values in days per visit · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Fruquintinib + BSC Group3.36.81Not reportedNot reportedNot reported
Placebo + BSC Group4.47.53Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        6.81
        value
        3.3
      2. group Id
        OG001
        spread
        7.53
        value
        4.4
denom Units Selected
Number of visits
denoms
  1. counts
    1. group Id
      OG000
      value
      461
    2. group Id
      OG001
      value
      230
    units
    Participants
  2. counts
    1. group Id
      OG000
      value
      545
    2. group Id
      OG001
      value
      232
    units
    Number of visits
description
Duration of hospital visit was calculated as = stop date - start date + 1. Mean and standard deviation data for duration of hospital visits (in days) by participants was reported in this outcome measure.
dispersion Type
Standard Deviation
groups
  1. description
    Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).
    id
    OG000
    title
    Fruquintinib + BSC Group
  2. description
    Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).
    id
    OG001
    title
    Placebo + BSC Group
param Type
MEAN
population Description
ITT population included all randomized participants.
reporting Status
POSTED
time Frame
From start of study drug administration up to 22 months
title
Health Care Resource Utilization: Duration of Hospital Visits by Participants
type
SECONDARY
type Units Analyzed
Number of visits
unit Of Measure
days per visit

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice